Astrazeneca

FromAstraZeneca ([email protected])
Subject (44)Gefurulimab nanobody met Phase III endpoints
Preheader (150)Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily livin
Typography
Arial
Colors
Text Analysis
Body Words170
Subject Words6
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px840 px
X-Spam Score1.6
Preheader OptimizedNo
Timing
Day of WeekWednesday
TimeAfternoon

Gefurulimab nanobody met Phase III endpoints

Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily livin
Gefurulimab nanobody met Phase III endpoints